Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

31 results about "Autosomal recessive inheritance" patented technology

Primer in use for in vitro diagnosing GJB2 mutation of deaf gene of autosomal recessive inheritance in non-syndrome

This invention provides primers for in vitro diagnosis of mutation of autosomal recessive nonsyndromic hearing loss gene GJB2. The primers can be used for completely amplifying the coding region and upstream or downstream important splicing sequences of GJB2 gene. This invention also provides a test kit for containing the primers and ApaI restriction endonuclease and their application for in vitro detection of 233-235delC mutation of the complete GJB2 coding region. The test kit can also be used for detecting the mutation sites of the GJB2 coding region through sequencing by the forward primer, and detecting deletion or insertion heterozygous mutation through sequencing by the reverse primer. The test kit is suitable for large-scale screening of autosomal recessive nonsyndromic hearing loss gene GJB2 mutation and genetic counseling.
Owner:山东三月三基因技术有限公司

Probe and kit for detecting common mutations of large vestibular aqueduct-related deafness gene

InactiveCN102559913ASimplified electrophoresis detectionSimplified purificationMicrobiological testing/measurementDNA/RNA fragmentationFluorescenceWild type
The invention relates to a real-time fluorescence quantitative probe and a kit for detecting IVS7-2A>G, which is one of 10 common mutations of an autosomal recessive inheritance large vestibular aqueduct-related deafness gene SLC26A4, wherein the kit comprises the real-time fluorescence quantitative probe. The wild-type probe is positioned at a site of 23403bp-23425bp; the mutant-type probe is positioned is positioned at a site of 23404bp-23425bp. In allusion to the Taqman mutant-type probe and the wild-type probe at mutation points and a pair of primers, the probes are high in specificity, high in sensitivity, and intuitive, accurate and reliable in test results, applicable to mass screening of the common mutation IVS7-2A>G of the autosomal recessive inheritance large vestibular aqueduct-related deafness gene SLC26A4 and rapid diagnosis of a SLC26A4 gene-related large vestibular aqueduct deafness.
Owner:GENERAL HOSPITAL OF PLA

Genetic risk early-warning method for auxiliary reproduction sperm supplying strategy and system

ActiveCN110364226AAvoid the risk of birth defectsExcellent gene pairingProteomicsGenomicsDisease riskGenetic risk
The invention provides a genetic risk early-warning method for auxiliary reproduction sperm supplying strategy and a system. According to the method and the system, an autosome recessive genetic disease reproduction genetic risk of a to-be-pregnant women is evaluated and predicted, and a sperm donation volunteer who has relatively high gene pairing degree and low genetic disease risk as a to-be-selected object. Quantification and automation for risk evaluation of a reproduction autosome recessive genetic disease are comprehensively realized. The method and the system have advantages of greatlyreducing manpower cost and time cost, realizing high reasonability, and greatly improving analysis accuracy.
Owner:FUDAN UNIV

Regulator of ephrin-Eph receptor signaling and mouse having abnormal ephrin-Eph receptor signaling mechanisms

InactiveUS20100242126A1Nervous disorderSugar derivativesAbnormal walkAxon extension
It is intended to provide an agent for regulating axon extension during neuranagenesis by regulating ephrin-Eph receptor signaling mechanisms and to provide a mouse having abnormal ephrin-Eph receptor signaling mechanisms. The present invention relates to a regulator of axon extension, comprising an agent for promoting or suppressing the function of α-chimerin, and to a miffy (mfy) mouse derived from a B6 strain, which displays autosomal recessive inheritance of an abnormal walking trait exhibiting a hopping gait with left-right synchronized movement of limbs and has mutation in an α-chimerin gene.
Owner:RIKEN

Oculocutaneous albinism type 1 related mutated TYR gene and application thereof to gene diagnosis

The invention discloses an oculocutaneous albinism type 1 related mutated TYR gene and application thereof to gene diagnosis. By collection of a 4-generation oculocutaneous albinism type 1 family, a transmission manner of 4-generation oculocutaneous albinism type 1 in the family is an autosomal recessive inheritance manner according to judgment; by reading of documents and online databases, possible pathogenic candidate genes are selected, then a propositus and other members in the family are subjected to PCR (polymerase chain reaction) amplification and Sanger sequencing to determine mutant gene loci, and consequently a TYR pathogenic gene (mutant c.107G) which is a novel pathogenic mutation is discovered. Discovery of the novel TYR pathogenic gene mutation locus enriches a pathogenic gene mutation spectrum, and the novel TYR pathogenic gene mutation locus can be used as a prenatal diagnosis screening locus for oculocutaneous albinism type 1 which is a serious recessive hereditary disease to guide prenatal and postnatal care. By providing of the oculocutaneous albinism type 1 related mutated TYR gene, data support is provided for design of prenatal diagnosis chips, and especially,important significance to prenatal gene diagnosis screening of seriously-harmful rare genetic diseases is achieved.
Owner:HARBIN MEDICAL UNIVERSITY

Detection kit for autosomal dominant inheritance polycystic kidney disease

The present invention relates to the field of detection technology in medical molecular physiology, it is a kit for detecting autosomal dominant inheritance polycystic kidney disease. According to the structure property of pathogenic gene type A and type B of patient said invention can synthesize correspondent primer, adopt molecular physiological techonlogy and combine it with single-strand conformation polymorphism analysis method or high-pressure liquid-phase chromatography analysis method to make detection, and can directly detect out the mutant site and mutation type of pathogenic gene of the autosomal recessive inheritance polycystic kidney disease for preventing and curing said disease.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY

Gene correction of pompe disease and other autosomal recessive disorders via rna-guided nucleases

Described herein are guide RNAs and modified guide RNAs suitable for biallelic correction of Pompe disease. Also included are methods of modifying a target gene in a patient or in a patient-derived cell, wherein the patient has an autosomal recessive disorder with compound heterozygous mutations, the methods including delivering a first modified guide RNA, a second modified guide RNA, a Cas9 polypeptide, a biotin-binding molecule, a first biotinylated donor polynucleotide, and a second biotinylated donor polynucleotide. The first modified guide RNA and the first biotinylated donor polynucleotide correct a first diseased allele, and the second modified guide RNA and the second biotinylated donor polynucleotide correct a second diseased allele.
Owner:WISCONSIN ALUMNI RES FOUND

Gene detection panel related to autosomal recessive genetic diseases and application of gene detection panel

The invention belongs to the field of gene detection, relates to a gene detection panel related to autosomal recessive genetic diseases and an application of the gene detection panel, and particularlyrelates to a gene detection panel for distinguishing methylmalonic acidemia, methylmalonic acidemia combined homocysteinemia and propionaemia. The application comprises the following steps: detecting43 mutation sites of four genes related to three diseases aiming at samples with high genetic metabolic disease screening preliminary screening (tandem mass spectrometry) C3, designing amplificationprimers aiming at the 43 mutation sites to amplify a target sequence, and designing a single-base extension primer to detect target SNP, through multiple PCR and multiple single-base extension reactions, carrying out mass spectrometry according to different genotype masses, and determining the genotype of each site, so that diseases with different prognosis and treatment means are distinguished ata time.
Owner:GENERAL HOSPITAL OF PLA

Application of NVP-BGJ398 in preparation of medicine for treating rMED

PendingCN114366742AImprove bending deformityPromote differentiationOrganic active ingredientsSkeletal disorderDiseaseEpiphyseal dysplasia
The invention discloses an application of NVP-BGJ398 in preparation of a medicine for treating rMED (recombinant epiphyseal dysplasia). The inhibitor NVP-BGJ398 can be used for treating an SLC26A2 mutant autosome recessive hereditary multiple epiphyseal dysplasia rMED disease; the NVP-BGJ398 intervenes the phenotype of the postnatal dysplasia disease, can improve the cartilage cell differentiation and collagen secretion conditions of a limb cartilage growth plate, and improves the development bending malformation conditions of lower limbs.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY +1

High-throughput sequencing variation risk grouping and screening method

The invention provides a high-throughput sequencing variation risk grouping and screening method. The method comprises the following steps: setting pathogenicity high-risk variation screening conditions, and screening gene data according to the pathogenicity high-risk variation screening conditions; setting pathogenicity high-risk variation screening conditions and medium-risk variation screening conditions with extremely low crowd frequency, and screening the gene data; setting pathogenicity medium-high risk variation screening conditions, and screening the gene data; setting gene variation screening conditions of pathogenicity medium and high risk autosomal dominant heredity, and screening the gene data; setting conditions of pathogenicity medium-high-risk autosomal recessive inheritance and the same gene, and screening the gene data; setting variation screening conditions of high-risk sex-linked inheritance in pathogenicity, and screening the gene data; and setting screening conditions for determining pathogenicity variation or suspicious pathogenicity variation with high risk in pathogenicity, and screening the gene data.
Owner:TIANJIN KINGMED CENT FOR CLINICAL CO LTD

Primary familial brain calcification pathogenic gene JAM2 and application thereof

The invention provides primary familial brain calcification pathogenic gene JAM2 and application thereof. Specifically, the invention provides application of JAM2 gene, or a protein thereof or a detection reagent thereof in preparation of a detection agent or a kit. The detection agent or the kit is used for detecting primary familial brain calcification and / or susceptibility of primary familial brain calcification. According to the invention, the JAM2 gene is identified as a new pathogenic gene for autosomal recessive inheritance of primary familial brain calcification for the first time; inaddition, a patient suffering from primary familial brain calcification and / or susceptibility thereof can be diagnosed by detecting the mutation of the JAM2 gene or the protein of the JAM2 gene.
Owner:ZHEJIANG UNIV

Mouse developing visceral fat type obesity and diabetes

An object of the present invention is to provide a mouse which has the characteristics of early developing visceral fat type obesity and also has concurrent diabetes and hyperlipemia and in which the trait is genetically established and recessively inherited. An ICR-derived mouse strain, Daruma, spontaneously developing obesity, exhibiting autosomal recessive inheritance for the trait of spontaneously developing obesity, and becoming obese only in the homozygous type is provided.
Owner:MIYAZAKI UNIV OF

Mouse developing visceral fat type obesity and diabetes

An object of the present invention is to provide a mouse which has the characteristics of early developing visceral fat type obesity and also has concurrent diabetes and hyperlipemia and in which the trait is genetically established and recessively inherited. An ICR-derived mouse strain, Daruma, spontaneously developing obesity, exhibiting autosomal recessive inheritance for the trait of spontaneously developing obesity, and becoming obese only in the homozygous type is provided.
Owner:MIYAZAKI UNIV OF

A mutated msh6 gene at position 12759 and its application

The present invention discloses that the MSH6 mutant gene with g.[12759inTTAAG] mutation is a new pathogenic gene of HR, and the sequence of the mutant fragment of the MSH6 mutant gene is shown in SEQ ID NO:3. The diploid homozygous genotype of the MSH6 mutant gene having the sequence shown in SEQ ID NO: 3 can lead to the occurrence of hypophosphatemic rickets in humans, and has SEQ ID NO: 3 and SEQ ID NO: 1, SEQ ID NO: 2, The diploid heterozygous genotype composed of any MSH6 mutation gene in the sequence shown in SEQ ID NO: 4 can also cause the occurrence of human hypophosphatemic rickets, and all of them are autosomal recessive inheritance. On this basis, the present invention provides two mutation detection kits based on PCR capture sequencing and conventional PCR and Sanger sequencing, which are of great significance for HR screening, diagnosis, and fertility guidance, and are especially helpful for Prevent the birth of children with HR at the source. In addition, the discovery of specific mutations in the MSH6 gene is also helpful for the exploration of the pathogenesis of HR and the development of therapeutic drugs and methods.
Owner:黄志玲

Application of valeric acid derivatives in treatment of hereditary cerebellar ataxia

The invention discloses an application of a compound shown in a formula I in preparation of medicines for preventing, treating or improving hereditary cerebellar ataxia, particularly autosomal recessive genetic spinal cerebellar ataxia 20(SCAR20). The compound provided by the invention can significantly improve the motor ataxia of a model mouse and slow down the death of Purkinje cells, thereby providing clinical support for the treatment of hereditary cerebellar ataxia, especially SCAR20.
Owner:XIAMEN UNIV

Family three-sample high-throughput sequencing risk grouping and screening method and system

The invention discloses a family three-sample high-throughput sequencing risk grouping screening method. The method comprises the following steps: S1, selecting markers for pathogenic high-risk gene variation of family three samples; s2, screening and marking gene variation of suspected new mutation of the pre-evidence sample; s3, selecting markers for pathogenicity medium and high risk autosomal dominant genetic gene variation; s4, screening and marking the pathogenicity medium-high-risk autosomal recessive inheritance gene variation; s5, screening markers for high-risk sex-linked heredity gene variation in pathogenicity; s6, screening and marking the gene variation with the suspected prenatal risk; the invention further discloses a family three-sample high-throughput sequencing risk grouping and screening system, rapid analysis of data is achieved, the analysis efficiency is greatly improved, and the accuracy is improved.
Owner:TIANJIN KINGMED CENT FOR CLINICAL CO LTD

MSH6 gene with mutated 12907th site, and application of MSH6 gene

The invention discloses that an MSH6 mutant gene which generates g.[12907inCAGC] mutation is a new pathogenic gene of HR, and the mutant fragment sequence of the MSH6 mutant gene is disclosed by SEQ ID NO:4. The diploid homozygous genotype of the MSH6 mutant gene which owns the sequence disclosed by the SEQ ID NO:4 causes generation of human hypophosphatemic rickets, a diploid heterozygous genotype formed by the MSH6 mutant gene which owns any one of the sequences disclosed by the SEQ ID NO:4 and SEQ ID NO:1- SEQ ID NO:3 also causes the generation of the human hypophosphatemic rickets, and inaddition, the human hypophosphatemic rickets are under autosomal recessive inheritance. On the basis, the invention provides two mutation detection kits on the basis of PCR capture sequencing and on the basis of conventional PCR and Sanger sequencing so as to generate an important meaning for HR screening, diagnosis and birth-giving guidance and be especially favorable for avoiding the birth of HRchild patients from the source. In addition, a revelation for the specific mutation of the MSH6 gene is also favorable for exploring HR pathogenesis and developing a treatment method and method.
Owner:黄志玲
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products